Explore

Trendline Trendline
Chai Discovery and Pfizer Collaborate to Enhance Drug Discovery with AI

Chai Discovery and Pfizer Collaborate to Enhance Drug Discovery with AI

Chai Discovery and Pfizer Collaborate to Enhance Drug Discovery with AI
Trendline Trendline
DaltonTx Launches AI-Powered Drug Discovery Platform with First Client

DaltonTx Launches AI-Powered Drug Discovery Platform with First Client

DaltonTx Launches AI-Powered Drug Discovery Platform with First Client
Trendline Trendline
Alnylam and Inceptive Partner to Accelerate RNAi Therapeutics Discovery with AI

Alnylam and Inceptive Partner to Accelerate RNAi Therapeutics Discovery with AI

Alnylam and Inceptive Partner to Accelerate RNAi Therapeutics Discovery with AI
Trendline Trendline
AstraZeneca CEO Highlights AI's Role in Enhancing Drug Development Success

AstraZeneca CEO Highlights AI's Role in Enhancing Drug Development Success

AstraZeneca CEO Highlights AI's Role in Enhancing Drug Development Success
Trendline Trendline
DaltonTx Launches AI Platform for Drug Discovery, Partners with Sygnature Discovery

DaltonTx Launches AI Platform for Drug Discovery, Partners with Sygnature Discovery

DaltonTx Launches AI Platform for Drug Discovery, Partners with Sygnature Discovery
Trendline Trendline
Alnylam Pharmaceuticals Partners with Inceptive Nucleics for AI-Driven Drug Development

Alnylam Pharmaceuticals Partners with Inceptive Nucleics for AI-Driven Drug Development

Alnylam Pharmaceuticals Partners with Inceptive Nucleics for AI-Driven Drug Development
Trendline Trendline
Bio-Techne and Refeyn Launch Integrated Workflow for Antibody Characterization

Bio-Techne and Refeyn Launch Integrated Workflow for Antibody Characterization

Bio-Techne and Refeyn Launch Integrated Workflow for Antibody Characterization
Trendline Trendline
Owkin and Sanofi Collaborate to Develop AI-Driven Biopharma Agents for Drug Discovery

Owkin and Sanofi Collaborate to Develop AI-Driven Biopharma Agents for Drug Discovery

Owkin and Sanofi Collaborate to Develop AI-Driven Biopharma Agents for Drug Discovery
Trendline Trendline
Incyte and Genesis Expand AI Drug Collaboration to Over $1 Billion

Incyte and Genesis Expand AI Drug Collaboration to Over $1 Billion

Incyte and Genesis Expand AI Drug Collaboration to Over $1 Billion
Trendline Trendline
Incyte and Genesis Expand AI Collaboration to Over $1 Billion for Drug Discovery

Incyte and Genesis Expand AI Collaboration to Over $1 Billion for Drug Discovery

Incyte and Genesis Expand AI Collaboration to Over $1 Billion for Drug Discovery
Trendline Trendline
Apoha Raises $36 Million to Advance AI with Liquid 'Wave Form' Data

Apoha Raises $36 Million to Advance AI with Liquid 'Wave Form' Data

Apoha Raises $36 Million to Advance AI with Liquid 'Wave Form' Data
Reuters Reuters
US FDA to review AI-based tool to predict drug-related liver damage

US FDA to review AI-based tool to predict drug-related liver damage

June 3 (Reuters) - The U.S. FDA's Center for Drug Evaluation and Research said on Wednesday it has accepted a letter of intent for an artificial intelligence-based drug development tool designed to help predict drug-induced liver injury.